Edoxaban, Warfarin Show Similar Thromboembolic, Bleeding Prevention After Bioprosthetic Valve Procedures
The direct oral anticoagulant edoxaban was shown to be noninferior to warfarin in preventing thromboembolism and major bleeding in the first 3 months after surgical bioprosthetic valve implantation or repair, according to study results presented Monday at the American College of Cardiology Scientific Sessions 2020 virtual conference.